Compare Sana Biotechnology Inc (SANA) vs TKO Group Holdings Inc (TKO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs TKO Group Holdings Inc — how do they compare? Sana Biotechnology Inc trades at $3.79 (market cap $1.13B), while TKO Group Holdings Inc trades at $195.16 (market cap $14.24B). The key difference: TKO Group Holdings Inc is far larger — about 12.6× Sana Biotechnology Inc's market cap, and TKO Group Holdings Inc pays a 1.6% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| SANA | TKO | |
|---|---|---|
Market Cap | $1.13B | $14.24B |
Sector | Health | Technology |
52-Week High | $5.92 | $224.96 |
52-Week Low | $2.68 | $176.49 |
Enterprise Value | $1.05B | $18.60B |
Dividend Yield | — | 1.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $3.77, up 4.43% today, with a bullish technical signal from moving averages and ADX indicators. The company reported a net loss of $244.17 million for 2025, with negative cash flow from operations, but analyst consensus is strongly positive with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 average price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress driving future profitability, but high cash burn and negative ROE pose significant risks. Upside potential exists if pipeline milestones are met, supported by institutional optimism, though investors face volatility from earnings misses and funding needs.
TKO trades at $195.15, up 3.03% today, with a bullish technical outlook supported by moving averages and strong institutional sentiment. The stock shows robust revenue growth, with Q2 2026 revenue reaching $1.55 billion (up 18% year-over-year, Business Wire, August 3, 2026), and raised full-year guidance. However, a high P/E ratio of 68.33 and mixed quarterly EPS results highlight valuation concerns amid solid operational performance.
The outlook remains positive due to strong media rights and live event momentum, but risks include earnings volatility and competitive pressures. Analyst consensus is strongly bullish with a $228.17 price target, suggesting ~17% upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About TKO Group Holdings Inc
TKO Group Holdings is a premium sports and entertainment company that serves as the parent entity for the Ultimate Fighting Championship (UFC) and World Wrestling Entertainment (WWE). Formed through a seismic merger orchestrated by Endeavor, TKO leverages a combined global fanbase of over 1 billion to drive massive revenue through media rights, global live events, and a unified sponsorship platform, effectively monopolizing the professional combat sports landscape.
Read more on TKO →
